Elligo Health Research Inc

1. Moderna TX, Inc. $44,303,058 22,446 payments
2. Pfizer Inc. $17,919,951 829 payments
3. Eli Lilly and Company $12,724,411 171 payments
4. Amgen Inc. $4,870,238 68 payments
5. Lexicon Pharmaceuticals, Inc. $3,865,101 359 payments
6. Sanofi US Services Inc. $3,413,682 335 payments
7. Genentech, Inc. $3,221,921 387 payments
8. Novartis Pharmaceuticals Corporation $2,985,503 54 payments
9. GlaxoSmithKline, LLC. $1,676,044 368 payments
10. Regeneron Pharmaceuticals, Inc. $1,617,028 192 payments

1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $12,314,793 604 payments
2. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $10,554,730 73 payments
3. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $7,229,635 10,637 payments
4. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $6,928,926 266 payments
5. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $5,735,092 8,176 payments
6. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $3,140,186 110 payments
7. A Phase 2 Randomized Doubleblind Placebo Controlled Dose Ranging Dose Finding Parallel Group Study to Assess Efficacy and Safety of Pf07081532 and Open Label Oral Semaglutide in Adults With Type 2 Diabetes Mellitus T2dm Inadequately Controlled on Metformin and Separately Pf07081532 Compared to Matching Placebo in Adults With Obesity But Without T2dm $3,120,465 30 payments
8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $2,743,818 17 payments
9. Lx9211.1-204-Dpn $2,400,788 221 payments
10. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $2,214,475 2 payments

1. Patient care $2,393,294 202 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.